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A B S T R A C T
Eluxadoline, an orally active mixed m opioid receptor (mOR) agonist d opioid receptor (dOR) antagonist
developed for the treatment of diarrhea-predominant irritable bowel syndrome, normalizes
gastrointestinal (GI) transit and defecation under conditions of novel environment stress or post-
inﬂammatory altered GI function. Furthermore, compared to loperamide, which is used to treat non-
speciﬁc diarrhea, the effects of eluxadoline on GI transit occur over a wider dosage range. However, the
mechanisms of action of eluxadoline are unclear. In this study, we compared the ability of eluxadoline
and loperamide to activate G-protein- and b-arrestin-mediated signaling at mOR homomers or mOR-dOR
heteromers in heterologous cells. We also examined the ability of both compounds to reduce castor oil
induced diarrhea in wild type (WT) and mice lacking dOR. We ﬁnd that eluxadoline is more potent than
loperamide in eliciting G-protein activity and b-arrestin recruitment in mOR expressing cells. However,
in cells expressing mOR-dOR heteromers, the potency of eluxadoline is higher, but its maximal effect is
lower than that of loperamide. Moreover, in these cells the signaling mediated by eluxadoline but not
loperamide is reduced by mOR-dOR heteromer-selective antibodies. We ﬁnd that in castor oil-induced
diarrhea eluxadoline is more efﬁcacious compared to loperamide in WT mice, and dOR appears to play a
role in this process. Taken together these results indicate that eluxadoline behaves as a potent mOR
agonist in the absence of dOR, while in the presence of dOR eluxadoline’s effects are mediated through
the mOR-dOR heteromer.
 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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Opioid receptors are therapeutic targets for the treatment of
pain. Morphine, the prototypic opioid, targets the mu opioid
receptor (mOR) and is clinically preferred for the treatment ofAbbreviations: GI, gastrointestinal; IBS-d, irritable bowel syndrome with diarrhea;
mOR, mu opioid receptor; dOR, delta opioid receptor; bgal, beta-galactosidase;
GTPgS, guanosine 50-O-(3-thiotriphosphate); DAMGO, [D-Ala2, N-MePhe4, Gly-ol]-
enkephalin; CB1R, cannabinoid receptor type1; AT1R, angiotensin II receptor type
1; ELISA, enzyme-linked immunosorbent assay; EC50, 50% effective concentration;
Emax, maximum effective concentration; WT, wild-type; /, knockout; eGFP,
enhanced green ﬂuorescent protein.
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0006-2952/ 2014 The Authors. Published by Elsevier Inc. This is an open access article unchronic pain [1]. However, chronic morphine administration leads
to a number of side-effects including development of analgesic
tolerance and constipation. Studies seeking to decrease the side-
effects associated with chronic morphine use found that delta
opioid receptor (dOR) antagonists could enhance morphine-
induced analgesia while preventing the development of tolerance
to this drug [2–6] which suggested interactions between mOR and
dOR. These interactions were examined using cells heterologously
expressing either mOR or dOR or a combination of both receptors
and showed that dOR selective antagonists, irrespective of their
nature (peptidic or non-peptidic), could enhance mOR selective
ligand binding and signaling only in cells co-expressing both
receptors [7,8]. Moreover, these in vitro studies showed that the
dOR antagonist decreased the dissociation rate of radioligand
bound to mOR [9]. These data supported the idea that the dOR
antagonist allosterically enhances mOR ligand binding leading to
potentiation of mOR-mediated signaling and antinociception. Oneder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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could occur is via the formation of mOR-dOR heteromers; mOR-
dOR heteromerization is supported by studies using antibodies
that selectively target the heteromer [10] or TAT peptides that can
disrupt the formation of mOR-dOR heteromers [11]. Ligands
targeting mOR-dOR heteromers either by having mOR agonist/
dOR antagonist activity such as bivalent ligands or ligands
possessing mixed mOR agonist and dOR antagonist activity have
been generated [12–17]. Studies using a bivalent ligand comprising
of a mOR agonistic pharmacophore separated by a 21-atom spacer
arm from a dOR antagonistic pharmacophore (MDAN21) [15,17]
showed that it exhibited 100-times higher antinociceptive
potency compared to morphine without signiﬁcant development
of tolerance or dependence [15]. Similarly, studies using ligands
possessing mixed mOR agonist/dOR antagonist activity show that
their chronic administration leads to lesser side-effects compared
to morphine [13]. Taken together these results suggest that
targeting the mOR-dOR heteromer could lead to the development
of drugs that are likely to have lower side effects than drugs
targeting mOR alone.
As mentioned above, one of the severe side-effects associated
with chronic morphine use is constipation; this suggests that
opioid receptors in the gastrointestinal (GI) tract could be targeted
for the treatment of GI tract disorders [18] such as diarrhea. This
led to the development of loperamide, a peripherally active mOR
agonist, as a therapeutic agent for the treatment of diarrhea
[19,20]. However, one of the side-effects associated with the use of
loperamide is the development of constipation [21,22]. The
possibility that drugs having mOR agonist/dOR antagonist activity
could have lesser side effects led to the synthesis of eluxadoline
[14,16]. Recent studies show that eluxodaline is a locally acting
mOR agonist/dOR antagonist that can normalize GI transit in
stressed animals over a wide dose range [16]. Eluxadoline has
limited systemic bioavailability which could potentially reduce its
effects on the central nervous system and consequently prevent
the development of side-effects associated with therapies cur-
rently used to treat irritable bowel syndrome with diarrhea (IBS-d).
Currently, eluxadoline has completed Phase II [23] and is
undergoing Phase III clinical trials for treatment of IBS-d. While
in vivo preclinical studies indicate that eluxadoline modulates GI
motility and decreases intestinal pain or visceral hyperalgesia
without the constipation associated with drugs that activate mOR
[16], its mechanism of action is not clear. Since eluxadoline is a
mixed mOR agonist/dOR antagonist [14,16,23], it is possible that it
may mediate its effects by targeting mOR-dOR heteromers.
Therefore, in this study we examined the mechanism of the in
vitro effects of eluxadoline by comparing its activity in cell lines
(using an assay that speciﬁcally examines heteromer signaling)
and in tissues from wild-type (WT) and knockout mice (dOR/ or
mOR/). Furthermore, we evaluated the extent to which eluxado-
line affects GI transit in WT and dOR/mice in a castor oil induced
model of diarrhea. We ﬁnd that eluxadoline-mediated signaling
can be signiﬁcantly, albeit partially, blocked by an mOR-dOR
heteromer selective antibody in cells co-expressing both receptors.
We also ﬁnd that eluxadoline is more effective in blocking castor
oil-induced diarrhea in WT mice as compared to dOR/ mice.
These results suggest that eluxadoline, at least in part, mediates its
effects by targeting mOR-dOR heteromers.
2. Methods
2.1. Cell culture
mbgalOR and mbgalOR-dOR expressing U2OS cells were a kind
gift from DiscoveRx (Fremont, CA, USA). mbgalOR cells expressing
mOR tagged with a ProLink/b-galactosidase (bgal) donor (PK)fragment at the C-terminal region and b-arrestin tagged with a
complementary bgal activator (EA) fragment were grown in MEM
alpha (Life Technologies, Grand Island, NY, USA) containing 10%
FBS (Biowest SAS, Nuaille, France), streptomycin-penicillin (Life
Technologies), 500 mg/ml geneticin (Life Technologies) and
250 mg/ml hygromycin (Life Technologies). mbgalOR-dOR cells
expressing wild-type dOR, mOR tagged with the PK fragment at the
C-terminal region and b-arrestin tagged with the EA fragment
were grown in MEM alpha containing 10% FBS, streptomycin-
penicillin, 500 mg/ml geneticin, 250 mg/ml hygromycin and
0.25 mg/ml puromycin (Life Technologies).
2.2. [35S]GTPgS binding
Membranes were prepared from the spinal cord of either WT
(Jackson Laboratories, Sacramento, CA, USA), dOR/ (Charles River
Laboratories, Kingston, NY, USA), mOR/ (a gift from Dr. Charles
Mobbs, Ichan School of Medicine at Mount Sinai, NY, USA) or from
the ileal longitudinal muscle (containing myenteric plexus) of WT
mice as described previously [24,25]. Membranes (10 or 20 mg)
were subjected to a [35S]GTPgS binding assay using DAMGO (R&D
Systems, Minneapolis, USA), loperamide (Toronto Research Che-
micals Inc., Ontario, Canada), eluxadoline (Furiex, Morrisville, NC,
USA) (0–10 mM ﬁnal concentration) in the presence or absence of
TIPPc (10 nM ﬁnal concentration) (a gift from Dr. Peter Schiller,
Institut de Reserches Cliniques de Montreal, Montreal, ON, Canada)
as described previously [25]. EC50 and Emax were calculated using
Prism 6 (GraphPad Software, Inc., La Jolla, CA, USA).
2.3. b-arrestin recruitment assay
U2OS cells expressing either mbgalOR or mbgalOR-dOR were plated
in each well (5000 cells) of a 96-well white clear bottom plate in
100 ml of media. Next day, cells were treated with either DAMGO,
loperamide, eluxadoline (0–10 mM ﬁnal concentration) in the absence
or presence of the dOR antagonist, TIPPc (10 nM ﬁnal concentration)
(a gift from Dr. Peter Schiller) or in the absence or presence of
antibodies (1 mg/well) to either mOR, mOR-dOR (generated as
reported in [26]) or cannabinoid receptor type1-angiotensin II
receptor type 1 heteromer (CB1R-AT1R) (generated as reported in
[27]) for 60 min at 37 8C. b-arrestin recruitment was measured
using the PathHunter Chemiluminescence detection kit as
described in the manufacturer’s protocol (DiscoveRx, Fremont,
CA, USA). EC50 and Emax were calculated using Prism 6 (GraphPad
Software, Inc., La Jolla, CA, USA).
2.4. Animals
Male C57BL/6 WT and dOR/ mice (25–35 g; 6–12 weeks old)
were obtained from either Jackson Laboratories (Sacramento, CA,
USA; WT mice) or Charles River Laboratories (Kingston, NY, USA;
dOR/mice). All mice were maintained on a 12-h light:12-h dark
cycle with rodent chow and water available ad libitum, and housed
in groups of ﬁve until testing. Animal studies were carried out
according to protocols approved by the Icahn School of Medicine at
Mount Sinai Animal Care and Use Committee.
2.5. Drug administration
Loperamide (Toronto Research Chemicals, Inc., Ontario,
Canada) and eluxadoline (Furiex, Morrisville, NC, USA) were
dissolved in 0.5% methylcellulose and 2% DMSO in water.
Corresponding vehicle was used for control group. Mice were
administered these drugs orally (p.o.). Naltrexone (R&D Systems,
Minneapolis, USA) was dissolved in saline and administered
intraperitoneally (i.p.). For chronic treatment with eluxadoline and
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10 mg/kg (p.o.) once a day for 5 days. On the 6th day, mice were
euthanized by cervical dislocation and ileum was collected (3–4
mice/sample) for ELISA assay.
2.6. Castor oil-induced diarrhea
Mice were placed in new absorbent lined bottomed cages with
no access to food and water for 2 h before the test. Immediately
before the test, the absorbent liner was discarded, and a fresh pre-
weighed liner was placed in the cage. Diarrhea was induced by oral
administration of castor oil (0.6 ml/mouse) (ACROS Organics, Geel,
Belgium) to WT or dOR/mice. Stools were scored (diarrhea score
of 0 = normal; 1 = wet and irregular shape; or 2 = shapeless) and
weighed over a 4-h period as described previously [28,29]. After
every hour, the absorbent liner was weighed, and another pre-
weighed liner was placed in the cage. Diarrhea score represents the
most marked change in feces for individual mice during a 4-h
period. Loperamide and eluxadoline were administered orally
15 min before the castor oil administration. When naltrexone
(10 mg/kg, i.p.) was used, it was administered 20 min before
loperamide or eluxadoline administration. Body weight was
measured before and 4 h after castor oil administration.
2.7. ELISA assay
Ileal longitudinal muscle (containing myenteric plexus) was
prepared as described previously [24]. Membranes (10 mg) from
mouse ileal longitudinal muscle were subjected to an ELISA assay
using rat anti-mOR antibody (1:500), rat anti-dOR antibody (1:500)
(generated as reported in [26]) or mouse anti-mOR-dOR heteromer
selective antibody (1:100) as primary antibodies and anti-mouse
IgG (1:1000) (Vector laboratories, Inc., Burlingame, CA., USA) or
anti-rat IgG (1:1000) (Jackson ImmunoResearch Laboratories, Inc.,
West Grove, PA, USA) coupled to horseradish peroxidase as
secondary antibodies as described previously [30]. ELISA for each
sample was performed in triplicate.
2.8. Statistical analysis
The data were expressed as means  S.E.M. Student’s t-test or
one-way ANOVA and multiple-comparison test (Student–Newman–
Keuls test or Dunnett’s test) were used to analyze the data. A
difference was considered to be signiﬁcant at p < 0.05.
3. Results
3.1. Eluxadoline-mediated signaling
Although phase II clinical studies show that eluxadoline, a
locally acting mixed mOR agonist and dOR antagonist, is effective in
the treatment of IBS-d patients [23] very little is known about its
cellular mechanism of action through heteromers. Therefore, we
determined the signaling of eluxadoline and compared it to that of
DAMGO, a selective mOR agonist, and of loperamide, a peripherally
active mOR agonist used in the treatment of diarrhea [19,20]. For
this, we measured G protein activity by carrying out [35S]GTPgS
binding assays using spinal cord membranes from WT, dOR/ or
mOR/ mice. We ﬁnd that DAMGO, the selective mOR agonist,
dose dependently increases [35S]GTPgS binding to spinal cord
membranes from WT (EC50  192 nM; Emax  143%) and from
dOR/ (EC50  188 nM; Emax  147%) but not from mOR/ mice
(Fig. 1A). Similarly, loperamide, the peripherally active mOR
agonist, dose dependently increases [35S]GTPgS binding to spinal
cord membranes from WT (EC50  63 nM; Emax  139%), dOR/
(EC50  29 nM; Emax  144%) but not from mOR/ mice (Fig. 1B).Interestingly, although eluxadoline like DAMGO and loperamide
did not increase [35S]GTPgS binding to membranes from mOR/
mice, it induced a dose dependent increase in [35S]GTPgS binding
to spinal cord membranes from WT mice with a higher potency
(EC50  7 nM) and lower efﬁcacy (Emax  120%) than seen with
either DAMGO or loperamide (Fig. 1C). Moreover, in membranes
from dOR/ mice the efﬁcacy of eluxadoline (Emax of 143%) was
higher than in WT membranes (Emax of 120%) and similar to that
seen with DAMGO in dOR/mice (Emax of 147%) (Fig. 1A and C).
These results suggest that a portion of eluxadoline-mediated
signaling in the presence of both mOR and dOR could be due to
activation of mOR-dOR heteromers since in the absence of dOR it
behaves like a pure mOR agonist.
Since eluxadoline is effective in the treatment of IBS-d [23] we
also carried out [35S]GTPgS binding assays using ileal membranes
from WT animals. We ﬁnd that eluxadoline, DAMGO and
loperamide cause dose-dependent increases in [35S]GTPgS binding
(Fig. 1D–F). Interestingly, we ﬁnd that in ileal membranes a
combination of the dOR antagonist, TIPPc, with the mOR agonist,
DAMGO, or eluxadoline (a mOR agonist/dOR antagonist) give a
higher increase in [35S]GTPgS binding compared to either DAMGO
or loperamide (mOR agonists) (Fig. 1G). These results would
suggest the presence of mOR-dOR heteromers in ileal tissue that
could contribute to the effectiveness of eluxadoline in the
treatment of IBS-d.
A common feature of GPCR signaling is that following receptor
activation, the receptor is phosphorylated by GRKs and this leads to
the recruitment of b-arrestin to the phosphorylated receptor,
cessation of G-protein mediated signaling and induction of b-
arrestin-mediated signaling (reviewed in [31]). Moreover, several
studies in the last decade show that some agonists preferentially
signal via one signaling pathway (for e.g., G protein-mediated)
versus another (for e.g., b-arrestin-mediated) leading to biased
agonism (reviewed in [31]). We therefore compared the ability of
DAMGO, loperamide and eluxadoline to induce b-arrestin
recruitment in cells expressing either mOR homomers (mbgalOR
cells) or mOR-dOR heteromers (mORbgal-dOR cells) using an
enzyme complementation assay that we recently used to identify
and characterize compounds that preferentially activate the mOR-
dOR heteromer [26]. Using this assay, we ﬁnd that eluxadoline is
more potent (i.e., lower EC50) at inducing b-arrestin recruitment
than DAMGO or loperamide in mbgalOR (Fig. 2A–C) or in mORbgal-
dOR cells (Fig. 2D–F). Interestingly, eluxadoline is less efﬁcacious
than DAMGO or loperamide in mORbgal-dOR cells suggesting that
it’s intrinsic dOR antagonistic activity could affect its ability to
induce b-arrestin recruitment (Fig. 2D–F). This is supported by our
previous observation that the dOR antagonist, TIPPc, decreased
DAMGO-mediated b-arrestin recruitment only in mORbgal-dOR
cells but not in mbgalOR cells [26]. We therefore examined the
effect of TIPPc on DAMGO-, loperamide- or eluxadoline-mediated
b-arrestin recruitment. We ﬁnd that TIPPc has no effect on b-
arrestin recruitment induced by either DAMGO, loperamide or
eluxadoline in mbgalOR cells (Fig. 2A–C). However, in cells
expressing mORbgal-dOR, TIPPc decreased DAMGO- or lopera-
mide-induced b-arrestin recruitment but not that induced by
eluxadoline (Fig. 2D–F). The lack of effect of TIPPc on eluxadoline-
mediated b-arrestin recruitment in mORbgal-dOR cells could be
because eluxadoline already exhibits antagonistic activity at dOR.
In this context, it is interesting to note that in mORbgal-dOR cells
the efﬁcacy of eluxadoline to elicit b-arrestin recruitment is 50%
lower (Emax  433%) than seen with DAMGO or loperamide
(Emax  863% and 956%, respectively). Together these results
indicate that a component of eluxadoline’s effects is different
from DAMGO or loperamide and is possibly through activation of
mOR-dOR heteromers. We tested this by using mOR-dOR hetero-
mer-selective antibodies that we have generated and previously
Fig. 1. Effect of DAMGO, loperamide and eluxadoline on G-protein activation. (A–C) Membranes (10 mg) from spinal cords of WT, mOR/ and dOR/mice were subjected to a
[35S]GTPgS binding assay using DAMGO (A), loperamide (B), and eluxadoline (C) (0–10 mM ﬁnal concentration) as described in Section 2. (D–G) Membranes (20 mg) from the
ileum of WT mice were subjected to a [35S]GTPgS binding assay using DAMGO (D and G), loperamide (E and G), and eluxadoline (F and G) (0–10 mM ﬁnal concentration) in the
presence or absence of TIPPc (10 nM ﬁnal concentration) as described in Section 2. (G) Represents Emax (% of basal) obtained with 10 mM ﬁnal concentration of DAMGO
(10 nM ﬁnal concentration of TIPPc), eluxadoline or loperamide. Basal values determined in the absence of the agonist were taken as 100%. Results are the mean  S.E.M. n = 3–9.
n.d., Not determined. *p < 0.05; **p < 0.01, Dunnett’s test.
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signaling [10,26]. Also, we had previously reported that activation
of dOR can lead to b-arrestin recruitment to mOR in mORbgal-dOR
cells and this can be blocked by mOR-dOR heteromer-selective
antibodies [26]. In agreement with these observations we ﬁnd that
deltorphin II (Delt II; R&D Systems, Minneapolis, USA), the dOR
selective agonist, induces b-arrestin recruitment to mOR in
mORbgal-dOR cells (Fig. 3B) but not to mbgalOR cells (Fig. 3A)
and this can be blocked by mOR-dOR heteromer-selective
antibodies and not by mOR-selective antibodies or by antibodies
selective to an unrelated heteromer, i.e., the CB1R-AT1R heteromer
(Fig. 3B). We ﬁnd that loperamide-mediated b-arrestin recruit-
ment both in mbgalOR (Fig. 3A) and mORbgal-dOR cells (Fig. 3B) is
signiﬁcantly blocked by mOR-selective antibodies but not by
antibodies selective for either the mOR-dOR or CB1R-AT1R
heteromer. This supports that loperamide exerts its effects by
activating mOR. In the case of eluxadoline, we ﬁnd that its ability to
induce b-arrestin recruitment is blocked by mOR-selective
antibodies by 40% in mbgalOR cells (Fig. 3A) and by 17% in
mORbgal-dOR cells (Fig. 3B). In addition, we ﬁnd that mOR-dORheteromer-selective antibodies block 27% of eluxadoline-mediated
b-arrestin recruitment in mORbgal-dOR cells (Fig. 3B) but have no
effect in mbgalOR cells (Fig. 3A); no effect of CB1R-AT1R heteromer-
selective antibodies on eluxadoline-mediated b-arrestin recruit-
ment was observed in either mbgalOR (Fig. 3A) or mORbgal-dOR cells
(Fig. 3B). Taken together these results suggest that in cells co-
expressing mOR and dOR a portion of eluxadoline-mediated
signaling occurs via activation of mOR-dOR heteromers while in
cells expressing only mOR eluxadoline functions as a mOR agonist.
3.2. Castor oil-induced diarrhea
Previous studies showed that eluxadoline can normalize GI
transit over a wider dose range compared to loperamide in WT
mice [16]. Although WT mice express both mOR and dOR in
myenteric plexus [32], not much is known about the contribution
of each receptor type or of mOR-dOR heteromers to the effects
of eluxadoline on GI transit. To investigate this we used WT and
dOR/ mice and compared the effects of eluxadoline and
loperamide on castor oil induced diarrhea. We ﬁnd that oral
Fig. 2. Effect of DAMGO, loperamide and eluxadoline on b-arrestin recruitment. Cells (5000/well) expressing either mbgalOR (A–C) or mbgalOR-dOR (D–F) were treated with
either DAMGO (A and D), loperamide (B and E), eluxadoline (C and F) (0–10 mM ﬁnal concentration) in the absence or presence of the dOR antagonist, TIPPc (10 nM ﬁnal
concentration) for 60 min at 37 8C and b-arrestin recruitment was measured as described in Section 2. Results are the mean  S.E.M. n = 4–12. *p < 0.05, **p < 0.01, vs. absence
of TIPPC, t-test.
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score) both in WT (Fig. 4A) and dOR/ mice (Fig. 4B). The castor
oil-induced diarrhea in WT mice was reduced by administration of
5 or 10 mg/kg of either loperamide or eluxadoline (Fig. 4A).
Moreover, this reduction in castor oil-induced diarrhea by either
loperamide or eluxadoline at 10 mg/kg were not observed if the
animals were pre-treated with the mOR antagonist, naltrexone
(Fig. 4A); studies have reported that antagonizing the activity of
opioid receptors, including mOR, has no effect on castor oil induced
diarrhea [33,34]. Interestingly, in dOR/ mice a 5 mg/kg dose of
either loperamide or eluxadoline did not signiﬁcantly reduce
castor oil-induced diarrhea (Fig. 4B); a higher dose of 10 mg/kg was
required to completely eliminate diarrhea in the case of
loperamide and partially eliminate in the case of eluxadoline
(Fig. 4B).
Next, we correlated in the same animals the diarrheal scores
with fecal output by measuring fecal weight. We ﬁnd that castor oil
administration signiﬁcantly increases the fecal output in WTFig. 3. Effect of mOR-dOR heteromer-selective antibody on eluxadoline-mediated signali
with either deltorphin II (Delt II), loperamide or eluxadoline (1 mM ﬁnal concentration)
heteromer or CB1R-AT1R heteromer for 60 min at 37 8C and b-arrestin recruitment wa
**p < 0.01, vs. no Ab treatment for each group, Dunnett’s test.(Fig. 5A) and dOR/mice (Fig. 5B). In addition, we ﬁnd that in WT
mice, treatment with either loperamide or eluxadoline signiﬁ-
cantly reduces the castor oil induced fecal output and the values
were below that seen with controls administered with vehicle
instead of castor oil (Fig. 5A). These effects were blocked by co-
administration of naltrexone (Fig. 5A). Similar results were
obtained in dOR/ mice (Fig. 5B) although a 5 mg/kg dose caused
a less pronounced decrease in fecal output compared to that seen
in WT animals for both loperamide and eluxadoline (Fig. 5A and B).
The fact that a 5 mg/kg dose of either loperamide or eluxadoline
signiﬁcantly decreased fecal output in dOR/ mice but had no
signiﬁcant effect on the diarrhea scores (Fig. 4B) in the same
animals could be due to the qualitative nature of the diarrhea
score. Taken together these results showing that eluxadoline (at
5 mg/kg) produced a lower blockade of diarrhea and fecal output in
dOR/mice compared to WT mice suggests that dOR and/or mOR-
dOR heteromers could contribute to its anti-diarrheal effect in WT
mice. Moreover, a dose-response effect with eluxadoline isng. Cells (5000 cells) expressing either mbgalOR (A) or mbgalOR-dOR (B) were treated
 in the absence or presence of antibodies (Ab, 1 mg/well) to either mOR, mOR-dOR
s measured as described in Section 2. Results are the mean  S.E.M. n = 4. *p < 0.05,
Fig. 4. Effect of loperamide and eluxadoline on castor oil-induced diarrhea. Diarrhea was induced by oral administration of castor oil (0.6 ml/mouse) in WT (A) or dOR/ (B)
mice. Stools were scored for diarrhea (0 = normal; 1 = wet and irregular shape; or 2 = shapeless) for 4 h as described in Section 2. Loperamide and eluxadoline (5 or 10 mg/kg)
were administered orally 15 min before the castor oil administration. Naltrexone (10 mg/kg, i.p.) was administered 20 min before loperamide or eluxadoline administration.
Results are the mean  S.E.M. n = 3–6. **p < 0.01, vs. vehicle control; ##p < 0.01, vs. castor oil alone; $$p < 0.01, vs. castor oil + loperamide (10 mg/kg, p.o.); yyp < 0.01, vs. castor
oil + eluxadoline (10 mg/kg, p.o), Student–Newman–Keuls test.
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that dOR activity may modulate eluxadoline’s effects on mOR in WT
mice and that eluxadoline behaves as a mOR agonist in mice that
lack dOR.
Next we examined the changes in body weight in WT and dOR/
mice and found that in both groups castor oil-induced diarrhea led to
decreases in body weight (Fig. 6A and B) and this was blocked by
loperamide and eluxadoline. Both loperamide and eluxadoline effects
could be partly blocked by naltrexone. Although not statistically
signiﬁcant, the amount of body weight change in dOR/ appeared
more robust compared to WT mice. Interestingly, the effect of
naltrexone was more pronounced in dOR/ mice (Fig. 6). The fact
that 5 mg/kg eluxadoline was less effective in dOR/ mice as
compared to the WT mice is consistent with the results with diarrhea
score and fecal output and further support a role for dOR (or mOR-
dOR heteromer) in this effect in WT mice.
3.3. Chronic eluxadoline treatment
We have previously reported/noted that chronic treatment
with morphine under a paradigm that leads to the development ofFig. 5. Effect of loperamide and eluxadoline on castor oil-induced diarrhea (fecal output)
or dOR/ (B) mice. Stools were collected and weighed during 4 h as described in Sectio
before the castor oil administration. Naltrexone (10 mg/kg, i.p.) was administered 20 m
n = 3–6. **p < 0.01, vs. vehicle control; ##p < 0.01, vs. castor oil alone; $$p < 0.01, vs. castor o
Student–Newman–Keuls test.tolerance causes an increase in mOR-dOR heteromer expression in
different brain regions [10]. Therefore, in this study we examined
whether mOR-dOR heteromers are present in myenteric neurons
from GI tissue and ascertained the effect of long-term treatment
with loperamide or eluxadoline on receptor expression and on
body weight. We ﬁnd that administration of these compounds at
the dose of 10 mg/kg/day for 5 days did not lead to signiﬁcant
changes in body weight (Fig. 7A), indicating that repeated oral
treatment with either drug would not affect the nutrient
absorptive function in intestine. In addition, using antibodies
selective for either mOR, dOR or mOR-dOR heteromers we can
detect the presence of mOR, dOR or mOR-dOR heteromers in mouse
ileal longitudinal muscle (containing the myenteric plexus)
(Fig. 7B). In vehicle treated animals levels of dOR appear to be
the highest, followed by levels of mOR and mOR-dOR heteromers.
These results support ﬁndings by a study reporting co-localization
of mOR and dOR in myenteric neurons [32]. In addition, we ﬁnd
that chronic treatment with loperamide or eluxadoline does not
induce signiﬁcant changes in the levels of mOR, dOR or mOR-dOR
heteromer levels in ileal longitudinal muscle preparations contain-
ing myenteric plexus from WT mice.. Diarrhea was induced by oral administration of castor oil (0.6 ml/mouse) in WT (A)
n 2. Loperamide and eluxadoline (5 or 10 mg/kg) were administered orally 15 min
in before loperamide or eluxadoline administration. Results are the mean  S.E.M.
il + loperamide (10 mg/kg, p.o.); yyp < 0.01, vs. castor oil + eluxadoline (10 mg/kg, p.o),
Fig. 6. Effect of loperamide and eluxadoline on castor oil-induced body weight change. Diarrhea was induced by oral administration of castor oil (0.6 ml/mouse) in WT (A) or
dOR/ (B) mice. Body weight was measured before and 4 h after castor oil administration. Loperamide and eluxadoline (5 or 10 mg/kg) were administered orally 15 min
before the castor oil administration. Naltrexone (10 mg/kg, i.p.) was administered 20 min before loperamide or eluxadoline administration. Results are the mean  S.E.M.
n = 3–6. **p < 0.01, vs. vehicle control; ##p < 0.01, vs. castor oil alone; $$p < 0.01, vs. castor-oil + loperamide (10 mg/kg, p.o.); yp < 0.05, yyp < 0.01, vs. castor oil + eluxadoline
(10 mg/kg, p.o), Student–Newman–Keuls test.
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Several studies have examined the pharmacological proﬁles of
mOR-dOR heteromers (reviewed in [35,36]). Among them a few
have demonstrated that occupancy of dOR enhances mOR activity.
Thus dOR selective antagonists were shown to enhance mOR ligand
binding, mOR ligand-mediated signaling and mOR-mediated (i.e.,
morphine-mediated) analgesia [7–9,37]. Furthermore, studies
showed that mice with reduced dOR levels (through the use of
antisense oligonucleotides) or dOR/ mice did not develop
tolerance or dependence to morphine [38,39]. Together these
studies indicate that the use of dOR antagonists could lead to a
decrease in the adverse effects associated with in vivo administra-
tion of mOR agonists. Based on this possibility a number of ligands
were synthesized that have dual mOR agonist and dOR antagonist
activity [13–15,17,26,40,41]. The earliest studies with a single
compound possessing mixed mOR agonistic and dOR antagonistic
activities involved peptide ligands [42]. These peptides were found
to produce potent antinociception with reduced tolerance
compared to morphine and no physical dependence was observed
upon chronic administration [42]. Among the non-peptide ligands
possessing mixed mOR agonistic and dOR antagonistic activities,
14-alkoxypyridomorphinans have been reported to induce potent
antinociception but diminished tolerance development as com-
pared to morphine [13]. However, to date it is not clear as to
whether these compounds exert their effects by binding to
individual mOR or dOR or by targeting the mOR-dOR heteromer.Fig. 7. Effect of chronic treatment of loperamide and eluxadoline on body weight (A) and o
loperamide or eluxadoline (10 mg/kg, p.o., once a day for 5 days), or with 0.5% methylcel
daily administration. Results are the mean  S.E.M. n = 6–7. (B) On 6th day, ileum was co
(containing the myenteric plexus) were subjected to an ELISA assay in as described in Secti
ELISA was performed in triplicate. Results are the mean  S.E.M. n = 5.In this study, we ﬁnd that loperamide, a mOR agonist, is more
potent but as efﬁcacious as DAMGO (a peptidic mOR agonist) in
promoting [35S]GTPgS binding while being more potent but less
efﬁcacious at recruiting b-arrestin in mbgalOR cells, suggesting that
it exhibits bias towards G-protein mediated signaling. Biased
signaling, i.e., the ability of some agonists to preferentially signal
via one signaling pathway (for e.g., G protein-mediated) versus
another (for e.g., b-arrestin-mediated) is being increasingly
reported for G-protein coupled receptors (reviewed in [31]).
Interestingly, eluxadoline, a mixed mOR agonist/dOR antagonist acts
as a mOR agonist in the absence of dOR, but exerts some of its effects
via the mOR-dOR heteromer in the presence of dOR. Importantly,
blockade of eluxadoline-mediated signaling by mOR-dOR heteromer
selective antibody supports the idea that this compound targets
mOR-dOR heteromers. Furthermore, the in vivo ﬁndings of the
differences in anti-diarrheal effect of lower dose of eluxadoline
between WT and dOR/ mice is consistent with the notion that,
eluxadoline, at least in part, targets mOR-dOR heteromers.
Previous studies that tested the anti-diarrheal effects of
eluxadoline in either novel-environment stressed mice or in
intracolonic mustard oil-induced intestinal inﬂammatory model
found that it reduces GI transit and fecal output [16]. Consistent
with this we ﬁnd that eluxadoline exhibits similar effects on castor
oil induced diarrhea (Figs. 4 and 5). However, in the present study
we ﬁnd that the lower dose (5 mg/kg) of eluxadoline slightly
reduced fecal output to below the vehicle control in WT mice (i.e.,
induced constipation). This is in contrast to previous reportsn receptor expression levels in ileal longitudinal muscle (B). Mice were treated with
lulose (0.1 ml/10 g; vehicle). (A) Body weight was measured immediately before the
llected (3–4 mice/sample). Membranes (10 mg) from mouse ileal longitudinal muscle
on 2. Tissues from 3 to 4 individual animals were pooled and collected as one sample.
W. Fujita et al. / Biochemical Pharmacology 92 (2014) 448–456 455showing that eluxadoline even at doses of 5–25 mg/kg did not
cause constipation in the novel-environment stressed mice model
of diarrhea [16]. These differences could be due to the differences
in the stressor used in the studies (novel environment vs. castor
oil) and the time period for measuring fecal output since Wade
et al. (2012) measured for only 1 h after the novel-environment
stress, while we measured for 4 h after castor oil injection. Castor
oil is known to release ricinoleic acid followed by alterations in ion
transport and water ﬂux in the intestine [43–46] leading to
increases in fecal output or diarrhea. In contrast, novel environ-
ment stress is a form of psychological stress that is accompanied by
behavioral changes like grooming, rearing and snifﬁng [47–49]. It
is known that the novel-environment-induced increase in fecal
output is mediated by an increase in corticotropin-releasing
hormone and thyrotropin-releasing hormone and by activation of
cholinergic and serotonergic neurons [50]. It is possible that these
differences as well as changes in the levels and/or activity of
intestinal mOR-dOR heteromers under these two assay conditions
are responsible for the observed differences.
Relatively few studies have examined the levels of opioid
receptor proteins in the GI tract. Using enhanced green ﬂuorescent
protein (eGFP)-tagged dOR (dOReGFP) expressing mice, the
distribution of dOR was found to be conﬁned to enteric neurons
and ﬁbers within the muscularis externa; submucosal plexus and
myenteric plexus [32]. This study also showed that, in the
myenteric ganglia, over 80% of dOReGFP positive myenteric
neurons co-expressed mOR, and 60% of mOR positive neurons
co-expressed dOReGFP [32]. This is consistent with a previous
study that showed co-localization of mOR and dOR in myenteric
neurons by immunohistochemistry [51]. These results suggest that
mOR-dOR heteromers are present in the myenteric neurons. In this
study, we detected the presence of mOR-dOR heteromers in ileal
longitudinal muscle of mice that includes myenteric neurons [24]
using mOR-dOR heteromer-selective antibodies. Together these
results support the presence of mOR-dOR heteromers in ileal
tissue.
Studies have shown that chronic morphine treatment leads to
increase in mOR-dOR heteromer levels in select brain regions
[10]. Moreover, mOR-dOR heteromerization changes morphine-
mediated signaling from G-protein- into b-arrestin mediated
which could contribute to side-effects such as the development of
analgesic tolerance [11,37,52]. Interestingly, b-arrestin2 knockout
mice exhibit less morphine-induced constipation than their WT
counterparts [53], indicating an involvement of b-arrestin
mediated signaling (potentially via mOR-dOR heteromers) in the
constipating effects of morphine [54]. However, chronic morphine
administration does not lead to development of tolerance to the
constipating side-effect [55–58]. This led us to wonder if intestinal
mOR, dOR, and mOR-dOR heteromer levels are altered following
chronic treatment with drugs. In this study we did not detect
signiﬁcant changes in mOR, dOR, and mOR-dOR heteromer levels in
the intestine following chronic treatment with either loperamide
or eluxadoline compared to controls treated with vehicle (Fig. 7).
However, preliminary studies detect a slight increase albeit not
signiﬁcant in mOR-dOR heteromer levels in ileum following
chronic morphine administration (data not shown). This would
suggest a differential regulation of mOR-dOR heteromer function in
brain and gut, which is consistent with what has been previously
reported [54].
The detection of mOR-dOR heteromers in mouse ileal tissue
together with the anti-diarrheal effect of eluxadoline and in vitro
data showing that eluxadoline-mediated signaling is reduced by
mOR-dOR heteromer-selective antibodies indicates that eluxado-
line, at least in part, mediates its effects by targeting mOR-dOR
heteromers in the intestine. This would suggest that intestinal
mOR-dOR heteromers could be a potential therapeutic target forthe treatment of GI tract disorders including IBS-d. However,
additional studies examining the level and changes in the
localization of mOR-dOR heteromers in the human GI tract
following IBS-d are required to demonstrate that the mOR-dOR
heteromer is a novel therapeutic target for the treatment of this
disorder.
In this study, we ﬁnd that in the absence of dOR, eluxadoline
behaves as a potent mOR agonist. However, co-expression of mOR
and dOR alters the signaling proﬁle of eluxadoline that can be
partly blocked by mOR-dOR heteromer-selective antibodies. Thus,
the actions of eluxadoline could, at least in part, be due to targeting
of mOR-dOR heteromers in the gut. In addition, we ﬁnd that
eluxadoline can block castor oil-induced diarrhea in WT mice and
this is attenuated in dOR/ mice indicating the involvement of
dOR probably through mOR-dOR heteromerization in the in vivo
effects of eluxadoline.
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